Lateral flow device for diagnosing microbial infections
Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.
1. A kit comprising:
a. an antibody which recognizes at least one epitope of a galactofuranose residue of a polysaccharide secreted by Aspergillus fumigatus , which is attached to a first agent which renders the antibody detectable on a solid surface, wherein the antibody which recognizes at least one epitope of the galactofuranose residue of the polysaccharide is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (V H ) domain encoded by SEQ ID NO:1 and a variable light (V L ) domain encoded by SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a V H domain encoded by SEQ ID NO:3 and a V L domain encoded by SEQ ID NO:4; monoclonal antibody 686 (MAb686) comprising a V H domain encoded by SEQ ID NO:5 and a V L domain encoded by SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a V H domain encoded by SEQ ID NO:7 and a V L domain encoded by SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a V H domain encoded by SEQ ID NO:9 and a V L domain encoded by SEQ ID NO:10;
b. a lateral flow device on which is immobilized a second agent capable of capturing the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide when it has reacted with said epitope; and
c. instructions on using the kit to detect a fungal infection by testing a urine sample of a human subject suspected of having, having, or susceptible to having a fungal infection,
wherein the antibody and the first and second agents are present in appropriate concentrations to detect the fungal antigen in the urine specimen.
2. The kit of claim 1 wherein the antibody which recognizes at least one epitope of the galactofuranose residue of the polysaccharide is monoclonal antibody 476 (MAb 476) comprising a V H domain encoded by SEQ ID NO:9 and a V L domain encoded by SEQ ID NO:10.
3. The kit of claim 1 wherein the first agent is an optically detectable label.
4. The kit of claim 3 wherein the optically detectable label is a latex bead impregnated with a fluorescent tag.
5. The kit of claim 1 wherein the lateral flow device comprises a solid surface along which the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide attached to the first agent can migrate by capillary action.
6. The kit of claim 1 wherein the second agent comprises an antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide.
7. The kit of claim 1 wherein also immobilized on the lateral flow device is a third agent capable of capturing the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide when it has not reacted with said epitope.
8. The kit of claim 7 wherein the lateral flow device comprises a solid surface along which the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide attached to the first agent can migrate by capillary action which has in order along the capillary flow path a sample application zone, an immobilized second agent and an immobilized third agent.
9. The kit of claim 1 also containing a desalting column for removing an inhibitor found in urine samples which interferes with the binding of the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide to such epitopes.
10. The kit of claim 1 wherein the instructions relate to the use of the kit to screen the human subject for a fungal infection.
11. An antibody which recognizes at least one epitope of a galactofuranose residue of a polysaccharide secreted by Aspergillus fumigatus wherein it is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (V H ) domain encoded by SEQ ID NO:1 and a variable light (V L ) domain encoded by SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a V H domain encoded by SEQ ID NO:3 and a V L domain encoded by SEQ ID NO:4; monoclonal antibody 686 (MAb686) comprising a V H domain encoded by SEQ ID NO:5 and a V L domain encoded by SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a V H domain encoded by SEQ ID NO:7 and a V L domain encoded by SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a V H domain encoded by SEQ ID NO:9 and a V L domain encoded by SEQ ID NO:10.
12. The antibody of claim 11 wherein it is attached to a first agent that renders it detectable.
13. The antibody of claim 12 wherein the first agent is an optically detectable label.
14. The antibody of claim 13 wherein the optically detectable label is a latex bead impregnated with a fluorescent tag.
15. The antibody of claim 11 wherein it is monoclonal antibody 476 (MAb 476) comprising a V H domain of SEQ ID NO:9 and a V L domain of SEQ ID NO:10.
16. The antibody of claim 11 wherein it is attached to a second agent by which it can be immobilized on a lateral flow device.
17. A method for diagnosing a microbial infection in a human subject suspected of having, having, or susceptible to having a fungal infection by detecting the presence of at least one polysaccharide comprising a galactofuranose residue in a urine sample of the human subject comprising:
a. contacting the urine sample with an antibody which recognizes at least one epitope of a galactofuranose residue of a polysaccharide secreted by Aspergillus fumigatus , which is attached to a first agent which renders the antibody detectable on a solid surface, wherein the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (V H ) domain encoded by SEQ ID NO:1 and a variable light (V L ) domain encoded by SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a V H domain encoded by SEQ ID NO:3 and a V L domain encoded by SEQ ID NO:4; monoclonal antibody 686 (MAb686) comprising a V H domain encoded by SEQ ID NO:5 and a V L domain encoded by SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a V H domain encoded by SEQ ID NO:7 and a V L domain encoded by SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a V H domain encoded by SEQ ID NO:9 and a V L domain encoded by SEQ ID NO:10;
b. contacting the urine sample with a lateral flow device on which is immobilized a second agent capable of capturing the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide when it has reacted with said epitope; and
c. detecting a fungal infection in accordance with instructions provided with a kit also containing the antibody and the lateral flow device.
18. The method of claim 17 wherein the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide is monoclonal antibody 476 (MAb 476) comprising a V H domain encoded by SEQ ID NO:9 and a V L domain encoded by SEQ ID NO:10.
19. The method of claim 17 wherein the first agent is an optically detectable label.
20. The method of claim 19 wherein the optically detectable label is a latex bead impregnated with a fluorescent tag.
21. The method of claim 17 wherein the lateral flow device comprises a solid surface along which the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide attached to the first agent can migrate by capillary action.
22. The method of claim 21 wherein also immobilized on the lateral flow device is a third agent capable of capturing the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide when it has not reacted with said epitope.
23. The method of claim 17 wherein a mechanism for removing an inhibitor found in urine samples which interferes with the binding of the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide to such epitopes is utilized.
24. The method of claim 17 wherein the diagnosis involves screening the human subject for the presence of a fungal infection.
25. The kit of claim 1 wherein the instructions are on using the kit to detect Invasive Aspergillosis by testing the urine sample of an immunocompromised human subject and the fungal infection is Invasive Aspergillosis.
26. The method of claim 17 wherein the human subject is immunocompromised and the fungal infection is Invasive Aspergillosis.